Hillsdale Investment Management Inc. Takes $7.92 Million Position in Aveanna Healthcare Holdings Inc. $AVAH

Hillsdale Investment Management Inc. purchased a new stake in shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 893,130 shares of the company’s stock, valued at approximately $7,922,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Aveanna Healthcare by 34.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company’s stock worth $35,850,000 after acquiring an additional 1,041,324 shares during the period. AustralianSuper Pty Ltd purchased a new stake in shares of Aveanna Healthcare during the third quarter valued at $15,743,000. Assenagon Asset Management S.A. bought a new stake in shares of Aveanna Healthcare in the third quarter worth approximately $7,356,000. First Eagle Investment Management LLC lifted its position in Aveanna Healthcare by 12.1% during the second quarter. First Eagle Investment Management LLC now owns 810,667 shares of the company’s stock valued at $4,240,000 after purchasing an additional 87,500 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Aveanna Healthcare by 103.9% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 664,890 shares of the company’s stock worth $3,477,000 after purchasing an additional 338,746 shares during the period. 87.96% of the stock is currently owned by institutional investors.

Aveanna Healthcare Trading Down 1.1%

NASDAQ AVAH opened at $7.34 on Friday. The company has a fifty day simple moving average of $8.45 and a two-hundred day simple moving average of $8.46. Aveanna Healthcare Holdings Inc. has a 12-month low of $3.67 and a 12-month high of $10.32. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. The stock has a market cap of $1.53 billion, a P/E ratio of 20.39 and a beta of 2.06.

Analyst Ratings Changes

Several research firms have recently weighed in on AVAH. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Raymond James Financial reissued an “outperform” rating and issued a $13.00 target price on shares of Aveanna Healthcare in a report on Friday, December 5th. BMO Capital Markets began coverage on Aveanna Healthcare in a report on Thursday, November 13th. They set an “outperform” rating and a $11.00 price target on the stock. Royal Bank Of Canada boosted their target price on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Thursday, January 15th. Finally, Truist Financial boosted their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $11.06.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Insider Activity

In other news, insider Edwin C. Reisz sold 60,769 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $438,144.49. Following the completion of the sale, the insider owned 1,447,057 shares of the company’s stock, valued at $10,433,280.97. The trade was a 4.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Deborah Stewart sold 11,181 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $80,615.01. Following the completion of the transaction, the chief accounting officer directly owned 301,807 shares of the company’s stock, valued at approximately $2,176,028.47. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 998,595 shares of company stock valued at $7,567,770 over the last 90 days. Company insiders own 7.80% of the company’s stock.

Aveanna Healthcare Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.